Gene · 580
Papers4,139
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 4,139
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma. | Cells | 2022 | 36428992 | PubTator, text mining | PubMed |
| BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. | Cancers (Basel) | 2022 | 36428712 | PubTator, text mining | PubMed |
| Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. | Front Immunol | 2022 | 36426352 | PubTator, text mining | PubMed |
| Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations. | Cancer Manag Res | 2022 | 36411744 | PubTator, text mining | PubMed |
| Prioritization of microRNA biomarkers for a prospective evaluation in a cohort of myocardial infarction patients based on their mechanistic role using public datasets. | Front Cardiovasc Med | 2022 | 36407428 | PubTator, text mining | PubMed |
Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2. | Ecancermedicalscience | 2022 | 36405946 | PubTator, text mining | PubMed |
| Emerging potential of ubiquitin-specific proteases and ubiquitin-specific proteases inhibitors in breast cancer treatment. | World J Clin Cases | 2022 | 36405275 | PubTator, text mining | PubMed |
| Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. | Breast Cancer Res | 2022 | 36401316 | PubTator, text mining | PubMed |
| Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment. | J Biol Chem | 2022 | 36395883 | PubTator, text mining | PubMed |
| Germline pathogenic variants associated with ovarian cancer: A historical overview. | Gynecol Oncol Rep | 2022 | 36388756 | PubTator, text mining | PubMed |
| Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes. | Front Oncol | 2022 | 36387226 | PubTator, text mining | PubMed |
| Lung adenocarcinoma relapse with emerging EGFR mutation following complete response of small cell lung cancer warrants routine re-biopsy: A case report. | Front Oncol | 2022 | 36387208 | PubTator, text mining | PubMed |
| Barriers, interventions, and recommendations: Improving the genetic testing landscape. | Front Digit Health | 2022 | 36386046 | PubTator, text mining | PubMed |
| A synonymous variant contributes to a rare Wiedemann-Rautenstrauch syndrome complicated with mild anemia via affecting pre-mRNA splicing. | Front Mol Neurosci | 2022 | 36385762 | PubTator, text mining | PubMed |
| FOXK2 transcription factor and its roles in tumorigenesis (Review). | Oncol Lett | 2022 | 36380871 | PubTator, text mining | PubMed |
| Partial Reduction in BRCA1 Gene Dose Modulates DNA Replication Stress Level and Thereby Contributes to Sensitivity or Resistance. | Int J Mol Sci | 2022 | 36362151 | PubTator, text mining | PubMed |
| Integrative Genomic Tests in Clinical Oncology. | Int J Mol Sci | 2022 | 36361916 | PubTator, text mining | PubMed |
| Risk Allele Frequency Analysis and Risk Prediction of Single-Nucleotide Polymorphisms for Prostate Cancer. | Genes (Basel) | 2022 | 36360276 | PubTator, text mining | PubMed |
| Biallelic PMS2 Mutations in a Family with Uncommon Clinical and Molecular Features. | Genes (Basel) | 2022 | 36360190 | PubTator, text mining | PubMed |
| DNA Damage-Induced RNAPII Degradation and Its Consequences in Gene Expression. | Genes (Basel) | 2022 | 36360188 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/580/papers?page=42